Insulet (NSDQ:PODD) touted real-world data today for its Omnipod insulin management system at the Congress of the European Association for the Study of Diabetes.
The data come from a study of nearly 39,000 patients with Type I and Type II diabetes who received insulin through the Omnipod system and had at least three months of data downloaded from Glooko’s cloud-based diabetes data management system.
Data showed that this use was linked with frequent fingerstick blood glucose testing using Abbott‘s (NYSE:ABT) integrated FreeStyle glucose meter, as well as high usage of the advanced features of Insulet’s Omnipod system, the company reported.
“These data represent a large portion of our U.S. customer base and provide valuable insights into patient behaviors and clinical outcomes in the real-world setting,” Dr. Trang Ly, Insulet’s VP & medical director, said in prepared remarks. “Our partnership with Glooko provides meaningful input into self-management patterns and blood glucose profiles, which inform our future innovation and allow clinicians to better care for their patients. We are excited about these positive results further evidencing the many benefits of our Omnipod System and we look forward to presenting additional details at the EASD meeting.”
The average glucose level was 186 mg/dL, Insulet said, which is equivalent to an estimated HbA1C of 8.1%. The data also showed that 36% of all patients used advanced pump features.
Nearly 3,400 people in the study used a continuous glucose monitor in parallel with Insulet’s Omnipod system. More people using CGM + Omnipod required less insulin and spent more time in a normal blood glucose range compared to their counterparts. The company also reported that 65% of the CGM + Omnipod group used advanced pump features.
The company said it plans to evaluate real-world data in other markets, including Europe – especially after it takes over the distribution and commercial responsibilities for Omnipod in Europe on July 1 next year.
“The ability for Insulet to deliver this level of insight through real-world data in patients using an insulin pump, continuous glucose monitoring and a data management system is impressive and represents a very promising platform for the development of future innovation,” Eric Renard, head of the dept. of endocrinology, diabetes & nutrition at Montpellier University Hospital, said.
PODD shares were trading at $58.94 apiece in mid-morning activity today, up 0.5%.
See the best minds in medtech live at DeviceTalks Boston on Oct. 2.
